c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma

被引:244
作者
Blasco, Rafael B.
Francoz, Sarah
Santamaria, David
Canamero, Marta [1 ]
Dubus, Pierre [2 ]
Charron, Jean [3 ]
Baccarini, Manuela [4 ]
Barbacid, Mariano [1 ]
机构
[1] CNIO, Biotechnol Programmes, E-28029 Madrid, Spain
[2] Univ Bordeaux, EA2406, F-33076 Bordeaux, France
[3] Univ Laval, CRCHUQ, Hotel Dieu Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada
[4] Univ Vienna, Ctr Mol Biol, Max F Perutz Labs, A-1030 Vienna, Austria
基金
欧洲研究理事会; 加拿大健康研究院;
关键词
ORAL MEK INHIBITOR; PHASE-II; TUMOR PROGRESSION; MAP KINASE; CANCER; BRAF; ERK; REVEALS; PATHWAY; GROWTH;
D O I
10.1016/j.ccr.2011.04.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have investigated the role of individual members of the Raf/Mek/Erk cascade in the onset of K-Ras oncogene-driven non-small cell lung carcinoma (NSCLC). Ablation of Erk1 or Erk2 in K-Ras oncogene-expressing lung cells had no significant effect due to compensatory activities. Yet, elimination of both Erk kinases completely blocked tumor development. Similar results were obtained with Mek kinases. Ablation of B-Raf had no significant effect on tumor development. However, c-Raf expression was absolutely essential for the onset of NSCLC. Interestingly, concomitant elimination of c-Raf and B-Raf in adult mice had no deleterious consequences for normal homeostasis. These results indicate that c-Raf plays a unique role in mediating K-Ras signaling and makes it a suitable target for therapeutic intervention.
引用
收藏
页码:652 / 663
页数:12
相关论文
共 50 条
  • [1] Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
    Barbie, David A.
    Tamayo, Pablo
    Boehm, Jesse S.
    Kim, So Young
    Moody, Susan E.
    Dunn, Ian F.
    Schinzel, Anna C.
    Sandy, Peter
    Meylan, Etienne
    Scholl, Claudia
    Froehling, Stefan
    Chan, Edmond M.
    Sos, Martin L.
    Michel, Kathrin
    Mermel, Craig
    Silver, Serena J.
    Weir, Barbara A.
    Reiling, Jan H.
    Sheng, Qing
    Gupta, Piyush B.
    Wadlow, Raymond C.
    Le, Hanh
    Hoersch, Sebastian
    Wittner, Ben S.
    Ramaswamy, Sridhar
    Livingston, David M.
    Sabatini, David M.
    Meyerson, Matthew
    Thomas, Roman K.
    Lander, Eric S.
    Mesirov, Jill P.
    Root, David E.
    Gilliland, D. Gary
    Jacks, Tyler
    Hahn, William C.
    [J]. NATURE, 2009, 462 (7269) : 108 - U122
  • [2] Mek2 is dispensable for mouse growth and development
    Bélanger, LF
    Roy, S
    Tremblay, M
    Brott, B
    Steff, AM
    Mourad, W
    Hugo, P
    Erikson, R
    Charron, J
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (14) : 4778 - 4787
  • [3] Requirement for Map2k1 (Mek1) in extra-embryonic ectoderm during placentogenesis
    Bissonauth, Vickram
    Roy, Sophie
    Gravel, Mathieu
    Guillemette, Stephanie
    Charron, Jean
    [J]. DEVELOPMENT, 2006, 133 (17): : 3429 - 3440
  • [4] Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    Bollag, Gideon
    Hirth, Peter
    Tsai, James
    Zhang, Jiazhong
    Ibrahim, Prabha N.
    Cho, Hanna
    Spevak, Wayne
    Zhang, Chao
    Zhang, Ying
    Habets, Gaston
    Burton, ElizabethA.
    Wong, Bernice
    Tsang, Garson
    West, Brian L.
    Powell, Ben
    Shellooe, Rafe
    Marimuthu, Adhirai
    Nguyen, Hoa
    Zhang, Kam Y. J.
    Artis, Dean R.
    Schlessinger, Joseph
    Su, Fei
    Higgins, Brian
    Iyer, Raman
    D'Andrea, Kurt
    Koehler, Astrid
    Stumm, Michael
    Lin, Paul S.
    Lee, Richard J.
    Grippo, Joseph
    Puzanov, Igor
    Kim, Kevin B.
    Ribas, Antoni
    McArthur, Grant A.
    Sosman, Jeffrey A.
    Chapman, Paul B.
    Flaherty, Keith T.
    Xu, Xiaowei
    Nathanson, Katherine L.
    Nolop, Keith
    [J]. NATURE, 2010, 467 (7315) : 596 - 599
  • [5] Ral GTPases: corrupting the exocyst in cancer cells
    Camonis, JH
    White, MA
    [J]. TRENDS IN CELL BIOLOGY, 2005, 15 (06) : 327 - 332
  • [6] A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal
    Catalanotti, Federica
    Reyes, Gloria
    Jesenberger, Veronika
    Galabova-Kovacs, Gergana
    Simoes, Ricardo de Matos
    Carugo, Oliviero
    Baccarini, Manuela
    [J]. NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2009, 16 (03) : 294 - 303
  • [7] Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memory
    Chen, AP
    Ohno, M
    Giese, KP
    Kühn, R
    Chen, RL
    Silva, AJ
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2006, 83 (01) : 28 - 38
  • [8] Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
    Cully, M
    You, H
    Levine, AJ
    Mak, TW
    [J]. NATURE REVIEWS CANCER, 2006, 6 (03) : 184 - 192
  • [9] Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
    De Roock, Wendy
    Jonker, Derek J.
    Di Nicolantonio, Federica
    Sartore-Bianchi, Andrea
    Tu, Dongsheng
    Siena, Salvatore
    Lamba, Simona
    Arena, Sabrina
    Frattini, Milo
    Piessevaux, Hubert
    Van Cutsem, Eric
    O'Callaghan, Chris J.
    Khambata-Ford, Shirin
    Zalcberg, John R.
    Simes, John
    Karapetis, Christos S.
    Bardelli, Alberto
    Tejpar, Sabine
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (16): : 1812 - 1820
  • [10] In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling
    Dumaz, Nicolas
    Hayward, Robert
    Martin, Jan
    Ogilvie, Lesley
    Hedley, Douglas
    Curtin, John A.
    Bastian, Boris C.
    Springer, Caroline
    Marais, Richard
    [J]. CANCER RESEARCH, 2006, 66 (19) : 9483 - 9491